Michigan Medicine Advanced Genitourinary Malignancies Symposium 2025

This one-day symposium is dedicated to the comprehensive management of genitourinary malignancies, including prostate, bladder, and kidney cancers. Hosted by the NCI-designated Rogel Cancer Center, the course emphasizes a transdisciplinary approach to reducing the cancer burden and advancing health equity. It serves as a critical update for clinicians, bridging the gap between cutting-edge research—such as novel biomarkers and cellular therapies—and standard clinical practice. The program highlights the University of Michigan’s role in leading groundbreaking clinical trials and refining standards of care for complex GU cases.
+ What You Will Learn
Attendees will be able to:

Understand and apply the latest diagnostic modalities for the classification and risk-stratification of genitourinary cancers.

Appreciate the rapidly evolving therapeutic landscape, specifically the increasing use of targeted agents, immunomodulators, antibody-drug conjugates (ADCs), and cellular therapies.

Identify impactful research findings that drive future diagnostic and prognostic strategies.

Navigate clinical nuances in managing “in-between” cases, such as localized prostate cancer with nodal PSMA avidity.

Evaluate the role of circulating tumor DNA (ctDNA) in risk-stratifying patients with Muscle-Invasive Bladder Cancer (MIBC).

+ Event Details

Date: Saturday, November 22, 2025

Time: 8:30 AM – 3:30 PM ET

Location: The Sheraton Ann Arbor, 3200 Boardwalk Dr, Ann Arbor, Michigan

+ Who Should Attend
This course is designed for the interdisciplinary team involved in GU oncology:

Physicians (Medical Oncologists, Urologists, Radiation Oncologists, Internists)

House Officers (Residents and Fellows)

Physician Assistants and Nurse Practitioners

Nurses

Other Healthcare Professionals involved in cancer care

+ Why Attend

Emerging Therapies: Gain specific insights into the “nuance” of using Antibody-Drug Conjugates (ADCs) in bladder cancer, moving beyond simple prescription to understanding toxicity and sequencing.

Precision Medicine: Learn how new tools like PSMA PET and ctDNA are redefining “localized” versus “metastatic” disease, directly impacting treatment decisions for prostate and bladder cancer patients.

Expert Faculty: Hear directly from Michigan Medicine leaders who are driving the research on SBRT for renal cell carcinoma and immunotherapy strategies.

 
+ Topics:

Immunotherapy for Localized Bladder Cancer – Universal Strategy or Tailored Approach
Risk Stratification in MIBC – The Emerging Role of ctDNA
From Targets to Toxicity – Clinical Nuance in ADC Therapy for Bladder Cancer
Metastatic Body Radiotherapy for Localized RCC – Emerging Evidence, Evolving Role
Choosing Wisely – Patient Selection for Adjuvant IO in Kidney Cancer
Metastatic RCC with Bulky Primary – Navigating the Balance Between Local and Systemic Therapy (Sarah Elizabeth Yentz, MD)
Metastatic RCC with Bulky Primary – Navigating the Balance Between Local and Systemic Therapy (Udit Singhal, MD)
Managing the ‘In-Between’ – Localized Prostate Cancer with Nodal PSMA Avidity
When to Scan and What to Use – Imaging the Biochemically Recurrent Prostate Cancer Patient
When to Scan and What to Use – Imaging the Biochemically Recurrent Prostate Cancer Patient
When to Radiate – Managing the Primary and Metastases in Low-Volume Metastatic Castrate Sensitive Prostate Cancer
Tailoring Systemic Treatment in Low-volume mCSPC – How Long and What to Choose
To PET or Not – Deciding the Best Imaging for Metastatic Prostate Cancer
Pluvicto and Docetaxel in Metastatic Castrate Resistant Prostate Cancer – Making the Right Choice for Your Patient (Sarah Elizabeth Yentz, MD)
Pluvicto and Docetaxel in Metastatic Castrate Resistant Prostate Cancer – Making the Right Choice for Your Patient (Sean R. Miller, MD)
Beyond Symptom Control The Evolving Role of Radiation in Metastatic Castrate Resistant Prostate Cancer
Germline Testing in Prostate Cancer What the Oncologist Needs to Know
Next Generation Sequencing in Metastatic Prostate Cancer When, Who, and Why